ResMed Inc. (RMD)
Here's Why ResMed (RMD) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ResMed Inc. (RMD) Q2 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q2 2025 Earnings Conference Call January 30, 2025 4:30 PM ET Company Participants Mike Ott - Senior Manager, IR Michael Farrell - Chairman and Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Dan Hurren - MST Davin Thillainathan - Goldman Sachs Lyanne Harrison - Bank of America Laura Sutcliffe - UBS Craig Wong-Pan - RBC Mike Matson - Needham & Company Anthony Petrone - Mizuho Group Mathieu Chevrier - Citi David Low - JPMorgan Brett Fishbin - KeyBanc Capital Markets Operator Welcome to the Q2 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Matt, and I'll be your operator for today's call.
ResMed: Digital Health Drives Q2 Growth
ResMed (RMD 1.89%), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst consensus forecasts with adjusted EPS of $2.43 topping the $2.32 estimate and revenue of $1.282 billion beating the expected $1.266 billion.
Compared to Estimates, ResMed (RMD) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ResMed (RMD) Tops Q2 Earnings and Revenue Estimates
ResMed (RMD) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $1.88 per share a year ago.
ResMed beats quarterly profit estimates on demand for sleep disorder devices
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.
ResMed (RMD) Earnings Expected to Grow: Should You Buy?
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
ResMed (RMD) is an Incredible Growth Stock: 3 Reasons Why
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why ResMed (RMD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed Gains 37.8% in a Year: What's Driving the Stock?
RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is concerning.
